Marco Hernández-Enríquez

Marco Hernández-Enríquez

Auto-generated profile, based on publicly available information

Marco Hernández-Enríquez

Cardiology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2018 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
PDF file
MHMarco Hernández‐Enríquez
Marco Hernández‐Enríquez
OLOlivier Lairez
Olivier Lairez
FCFrancisco Campelo‐Parada
Francisco Campelo‐Parada
TLThibault LHERMUSIER
Thibault LHERMUSIER
FBFrédéric Bouisset
Frédéric Bouisset
NBNicolas Boudou
Nicolas Boudou

21 October 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MHMarco Hernández‐Enríquez
Marco Hernández‐Enríquez
LBLoic Belle
Loic Belle
HMHende Madiot
Hende Madiot
MPMichel Pansieri
Michel Pansieri
GSGeraud Souteyrand
Geraud Souteyrand
NBNicolas Boudou
Nicolas Boudou

1 August 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MHMarco Hernández-Enriquez
Marco Hernández-Enriquez
RARut Andrea
Rut Andrea
SBSalvatore Brugaletta
Salvatore Brugaletta
PJPilar Jiménez-Quevedo
Pilar Jiménez-Quevedo
JHJosé María Hernández-García
José María Hernández-García
MTManel Sabaté Tenas
Manel Sabaté Tenas

1 April 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MHMarco Hernández-Enríquez
Marco Hernández-Enríquez
TCThomas Chollet
Thomas Chollet
VBVincent Bataille
Vincent Bataille
FCFrancisco Campelo-Parada
Francisco Campelo-Parada
NBNicolas Boudou
Nicolas Boudou
TLThibault LHERMUSIER
Thibault LHERMUSIER

1 September 2016 in Resuscitation
Verified
Journal Article
Closed access
GJGustavo Jiménez-Brítez
Gustavo Jiménez-Brítez
XFXavier Freixa
Xavier Freixa
EFEduardo Flores
Eduardo Flores
DPDiego Penela
Diego Penela
MHMarco Hernandez-Enríquez
Marco Hernandez-Enríquez
MTManel Sabaté Tenas
Manel Sabaté Tenas

25 January 2018 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
MHMarco Hernández‐Enríquez
Marco Hernández‐Enríquez
FCFrancisco Campelo‐Parada
Francisco Campelo‐Parada
TLThibault LHERMUSIER
Thibault LHERMUSIER
FBFrederic Bouisset
Frederic Bouisset
Jerome RoncalliJerome Roncalli
Jerome Roncalli
NBNicolas Boudou
Nicolas Boudou
Objectives: To analyze the procedural and long‐term outcomes of the use of rotational atherectomy (RA) in underexpanded stents in our cohort and to provide an overview of currently available data on this technique.Background: Stent underexpansion (SU) has been related to stent thrombosis and restenosis. RA has been used to treat undilatable SU as a bail‐out strategy with encouraging results.Methods: This is an observational, single‐center study. We included patients who underwent stentablation between 2013 and 2017. Baseline demographics, procedural results, in‐hospital major adverse cardiac events (MACE), and long‐term follow‐up MACE were retrospectively collected.Results: A total of 11 patients (90.9% males, mean age 65.4 ± 18.6) were included in this study. Median left ventricle ejection fraction was 53.5% [46.2‐55]. Median calculated Syntax score was 16 [9‐31] and 45.5% of patients were admitted for acute coronary syndrome. Radial approach was used in 63.6% of cases. Most patients only required one burr (45% used a 1.5 mm diameter burr) during the intervention. Procedural success was achieved in 90.9% of the cases. Acute lumen gain was 42.7% [30.7‐61.49]. There were no in‐hospital deaths or MACE. At a median follow‐up of 26 months, only one patient (9.1%) suffered MACE in the context of acute coronary syndrome, and two patients (18.2%) required non‐target lesion revascularization. No deaths were reported.Conclusions: RA of under expanded stents is a feasible option with a high rate of procedural success. At long‐term follow‐up, all of them were alive and 90.9% of patients remained free from MACE.